Observational studyRespiratory research2026
Epithelial CD155-TIGIT/CD226 signaling links CD8⁺ T-cell exhaustion to frequent exacerbations in COPD.
Observational study in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe immune mechanisms underlying chronic obstructive pulmonary disease (COPD) remain incompletely understood, particularly regarding immune checkpoint dysregulation. This cross-sectional observational study aimed to determine whether activation of the T-cell immunoglobulin and ITIM domain (TIGIT) pathway contributes to CD8-positive T-cell exhaustion and susceptibility to frequent exacerbations in COPD.
methodsWe integrated publicly available single-cell RNA sequencing data from human lung tissue with analyses of peripheral blood, bronchoalveolar lavage fluid, and lung tissue obtained from patients with COPD and healthy controls. Flow cytometry was used to assess CD8-positive T-cell differentiation and expression of TIGIT and its co-stimulatory counterpart CD226, while immunohistochemistry quantified the TIGIT ligand CD155 in airway and alveolar epithelium. Functional assays, including cytokine production, apoptosis, and lentiviral TIGIT knockdown, were conducted to evaluate the reversibility of TIGIT-mediated exhaustion.
resultsSingle-cell and flow-cytometric analyses revealed an expansion of terminally differentiated effector memory CD8-positive T cells re-expressing CD45RA with high TIGIT expression in COPD, particularly among frequent exacerbators. CD155 was upregulated in airway and alveolar epithelial cells, whereas CD226 expression on CD8-positive T cells was reduced. TIGIT-positive CD8-positive T cells exhibited decreased tumour necrosis factor-alpha and interferon-gamma production and increased apoptosis. TIGIT knockdown restored cytokine secretion and reduced apoptosis, indicating a reversible exhausted phenotype.
conclusionThe TIGIT-CD155/CD226 pathway is associated with epithelial stress, CD8⁺ T-cell exhaustion and frequent exacerbations in COPD. Targeting this immune checkpoint may help restore antiviral immunity and reduce airway damage, providing a promising therapeutic avenue for immune modulation in chronic airway disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.